-
公开(公告)号：US20240101710A1
公开(公告)日：2024-03-28
申请号：US18468854
申请日：2023-09-18
Applicant: ALLOGENE THERAPEUTICS, INC. , PFIZER INC.
Inventor： Zea Melton , Tao Sai , Thomas John Van Blarcom
IPC: C07K16/42 , A61K49/00 , C07K1/22 , C07K16/28 , C12N5/0783 , G01N33/569
CPC classification number: C07K16/4266 , A61K49/0058 , C07K1/22 , C07K16/2878 , C12N5/0636 , G01N33/56972 , C07K2317/622 , C12N2501/998
Abstract: Provided herein are anti-idiotype antibodies that specifically recognize anti-BCMA antibody moieties, in particular, anti-BCMA antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of anti-idiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-BCMA CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.
-
公开(公告)号：US20230002498A1
公开(公告)日：2023-01-05
申请号：US17830324
申请日：2022-06-01
Applicant: Pfizer Inc.
Inventor： Siler Panowski , Tao Sai , Barbra Johnson Sasu , Surabhi Srivatsa Srinivasan , Thomas John Van Blarcom
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
Patent Agency Ranking
公开(公告)号：US20190233529A1
公开(公告)日：2019-08-01
申请号：US16264485
申请日：2019-01-31
Applicant: Pfizer Inc.
Inventor： Siler Panowski , Tao Sai , Barbra Johnson Sasu , Surabhi Srivatsa Srinivasan , Thomas John Van Blarcom
CPC classification number: C07K16/2875 , A61K2039/505 , A61P35/00 , C07K16/2809 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
公开(公告)号：US20190233528A1
公开(公告)日：2019-08-01
申请号：US16264371
申请日：2019-01-31
Applicant: Pfizer Inc.
Inventor： Surabhi Srivatsa Srinivasan , Niranjana Aditi Nagarajan , Siler Panowski , Yoon Park , Tao Sai , Barbra Johnson SASU , Thomas John Van Blarcom , Mathilde Brunnhilde Dusseaux , Roman Ariel Galetto
IPC: C07K16/28 , C07K14/725 , A61K39/00 , A61P35/02 , A61P35/04
CPC classification number: C07K16/2875 , A61K39/001129 , A61K39/001138 , A61K2039/5156 , A61P35/02 , A61P35/04 , C07K14/7051 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/02 , C07K2319/03 , C07K2319/33
Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
-
公开(公告)号：US12152081B2
公开(公告)日：2024-11-26
申请号：US17843616
申请日：2022-06-17
Applicant: Pfizer Inc.
Inventor： Surabhi Srivatsa Srinivasan , Niranjana Nagarajan , Siler Panowski , Yoon Park , Tao Sai , Barbra Sasu , Thomas Van Blarcom , Mathilde Dusseaux , Roman Galetto
IPC: C07K16/28 , A61K39/00 , A61P35/02 , A61P35/04 , C07K14/725
Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).
-
公开(公告)号：US11987634B2
公开(公告)日：2024-05-21
申请号：US17830324
申请日：2022-06-01
Applicant: Pfizer Inc.
Inventor： Siler Panowski , Tao Sai , Barbra Johnson Sasu , Surabhi Srivatsa Srinivasan , Thomas John Van Blarcom
CPC classification number: C07K16/2875 , A61P35/00 , C07K16/2809 , A61K2039/505 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
公开(公告)号：US11377500B2
公开(公告)日：2022-07-05
申请号：US16264485
申请日：2019-01-31
Applicant: Pfizer Inc.
Inventor： Siler Panowski , Tao Sai , Barbra Johnson Sasu , Surabhi Srivatsa Srinivasan , Thomas John Van Blarcom
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
-
-
-
-
-
-
Search Results
7
records
(took 0.024 seconds)
